Return to Home [X]

Exciting News: Introducing the New Essential Evidence Plus!

We are thrilled to announce that a brand-new version of Essential Evidence Plus is on its way! Mark your calendars for the launch date, September 11th, as we are introducing a modern, mobile-first application that will revolutionize your experience. With this update, accessing our valuable content will be easier and more convenient than ever before.

What to Expect from the New Essential Evidence Plus:

  1. Modern Mobile-First Experience: Our new application has been meticulously designed with a mobile-first approach. No matter what device you're using, whether it's a smartphone, tablet, or desktop, you'll enjoy a seamless and intuitive user experience.
  2. Enhanced Accessibility: We understand the importance of accessing content from anywhere, at any time. The new Essential Evidence Plus will provide you with the flexibility to explore our extensive collection of evidence-based resources on the go, making it easier to stay up to date with the latest medical knowledge and interactive tools.
  3. Improved User Interface: We have revamped our user interface to ensure effortless navigation and a visually appealing experience. Finding the information, you need will be quicker and more intuitive, saving you valuable time and effort.

Essential Evidence Plus will be available to users during this transition. However, please note that ability to create new trial and individual subscriptions will not be available from September 8th to September 11th 7:00 AM EST. During this period, we will be working diligently to transfer our existing system to the upgraded platform, ensuring a seamless transition for all users.

We apologize for any inconvenience caused by this temporary interruption. Rest assured, our team is committed to bringing you a superior user experience, and we appreciate your patience and understanding during this time.

Stay Tuned for the New Essential Evidence Plus!

We are counting down the days until September 11th when the new Essential Evidence Plus will be available for you to explore. Get ready to unlock a wealth of evidence-based resources that empower you in your medical decision-making process.

Thank you for your continued support, and we look forward to delivering an exceptional experience with the all-new Essential Evidence Plus!

Essential Evidence Plus

Browse Databases and Tools

Sort by Show per page
  • Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
    Cochrane Systematic Reviews, 13-Feb-2019
  • Aquatic exercise for the treatment of knee and hip osteoarthritis
    Cochrane Systematic Reviews, 23-Mar-2016
  • Aquatic exercise training for fibromyalgia
    Cochrane Systematic Reviews, 20-Oct-2014
  • Aqueous shunts for glaucoma
    Cochrane Systematic Reviews, 28-Jul-2017
  • Aqueous shunts with mitomycin C versus aqueous shunts alone for glaucoma
    Cochrane Systematic Reviews, 19-Apr-2019
  • Area‐wide traffic calming for preventing traffic related injuries
    Cochrane Systematic Reviews, 20-Jan-2003
  • Arginine supplementation for prevention of necrotising enterocolitis in preterm infants
    Cochrane Systematic Reviews, 11-Apr-2017
  • Argon plasma coagulation therapy for acute non-variceal upper gastrointestinal bleeding
    Cochrane Systematic Reviews, 5-Aug-2009
  • Aripiprazole (intramuscular) for psychosis‐induced aggression or agitation (rapid tranquillisation)
    Cochrane Systematic Reviews, 8-Jan-2018
  • Aripiprazole alone or in combination for acute mania
    Cochrane Systematic Reviews, 17-Dec-2013
  • Aripiprazole for autism spectrum disorders (ASD)
    Cochrane Systematic Reviews, 26-Jun-2016
  • Aripiprazole for schizophrenia
    Cochrane Systematic Reviews, 28-Feb-2013
  • Aripiprazole versus other atypical antipsychotics for schizophrenia
    Cochrane Systematic Reviews, 2-Jan-2014
  • Aripiprazole versus placebo for schizophrenia
    Cochrane Systematic Reviews, 4-Jul-2011
  • Aripiprazole versus typical antipsychotic drugs for schizophrenia
    Cochrane Systematic Reviews, 16-Jul-2008
  • Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome
    Cochrane Systematic Reviews, 27-Sep-2022
  • Aromatase inhibitors for short stature in male children and adolescents
    Cochrane Systematic Reviews, 7-Oct-2015
  • Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
    Cochrane Systematic Reviews, 7-Oct-2009
  • Aromatase inhibitors for uterine fibroids
    Cochrane Systematic Reviews, 22-Oct-2013
  • Aromatherapy and massage for symptom relief in patients with cancer
    Cochrane Systematic Reviews, 11-Jun-2013

Login or Subscribe


Not Yet a Subscriber?

Doctor with handheld

We offer subscriptions for individuals and institutions

To find out about all the benefits of a year-long subscription to Essential Evidence Plus, click the button below!

Learn More